Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.84% higher to $402.70 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.43 ...

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) shareholders might be concerned after seeing the share price ...

Investors in Vertex Pharmaceuticals Incorporated VRTX need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2025 $145 Call had some of the ...

The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% ...

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, ...

Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a ...

Vertex Pharmaceuticals' suzetrigine shows promising results in treating painful lumbosacral radiculopathy, but stock falls ...